CC-90005
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $3,150 | 2 | 2 |
| 2018 | $1,500 | 1 | 1 |
| 2017 | $116,857 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $121,507 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects with Moderate to Severe Plaque-type Psoriasis (CC-90005-CP-001) | Celgene Corporation | $3,150 | 2 |
| CC-90005-CP-001 - A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subj | Celgene Corporation | $1,500 | 1 |
Manufacturing Companies
- Celgene Corporation $121,507
Product Information
- Type Drug
- Total Payments $121,507
- Total Doctors 2
- Transactions 4
About CC-90005
CC-90005 is a drug associated with $121,507 in payments to 2 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $3,150 was paid across 2 transactions to 2 doctors.
The most common payment nature for CC-90005 is "Unspecified" ($121,507, 100.0% of total).
CC-90005 is associated with 2 research studies, including "A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects with Moderate to Severe Plaque-type Psoriasis (CC-90005-CP-001)" ($3,150).